Skip to main content
OpenTrials
Completed

NCT Number: NCT00388128

Caffeine and Intermittent Claudication

The purpose of this study is to evaluate the change in Walking capacity after an intake of caffeine. The study design is cross-over and follow-up of 80 patients with leg pain caused by narrowing of their leg arteries, Peripheral Vascular Disease (PAD), stage II. Half of all will be revascularised, follow up will be after 3 months. It is hypothesized that caffeine (6mg/kg) can be a cheap, safe drug before walking exercise. Primary endpoint is maximum walking distance (MWD), treadmill-testing,(constant load, 0%,2m/h). Secondary endpoints are pain free walking distance (PWD), maximum muscle strength, endurance, reaction speed, balance, cognitive function, health related quality of life (SF-36).

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Herning Hospital, Surgical research dep.

Herning, Central Jutland, 7400, Denmark

About this study

PAD has a prevalence of 15-20 % in an elderly (>50) western population. PAD can not be seen in isolation but represents the peripheral manifestation of a generalized artherosclerosis. The co-morbidity with coronary or cerebralartherosclerosis depends on the degree of severity of PAD, the relative risk of a death (predominantly cardiac) is increased by a factor 4. From af medical and a socio-economic point of view there is the need to control the PAD complication rate and related treatment costs as effectively as possible.

The aim of any treatment of intermittent claudication is a clinically relevant improvement in the patient´s mobility and quality of life.

There is agreement, that physical training does improve the collateralisation of vascular lesions, the rheologic properties of blood and lead to a shift from glycolytic to oxidative muscle fibers in the working musculature which increases the capillary density. The effect of physical training is also to modify the patients risk factor profile, even moderate training increase the insulin receptor sensitivity and the fibrinolytic activity and decrease the dLDL/HDL ratio and the diastolic blood pressure in hypertensive patients - and thereby decrease the overall cardiac mortality.

This is a Phase 3, 12-week, double-blind, randomized, placebo-controlled cross-over and a follow-up study with 80 patients with intermittent claudication, half of which will be revascularized.

The objectives of this study are to evaluate the efficacy of caffeine (6mg/kg)and the revascularisation procedure. The primary end-point will be maximal walking distance (MWD) in both groups of patients. Other efficacy measures will include claudication onset time (PWD), changes in Ankle Brachial Index (ABI), Quality of Life (QoL), cognitive function, plasma response of Vascular Endothelian Growth Factor (VEGF, FGF). Safety variables will include routine hematology parameters and adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • men and women > 40 years
  • history of IC of the lower extremities, Fontaine II
  • ankle-brachial index (ABI)> 0.9 (subjects who are referred for a revasularizarition procedure)

Exclusion criteria

  • dementia
  • diabetes
  • illness or reason to be unable to participate, f.ex. general weakness, amputation or arthritis
  • acute illness, f.ex. inflammation, unstable angina
  • other reasons which contraindicate participation/treadmill exercise
  • intake of Trental and/or Teofyllamin
  • weight > 100kg

Treatment and study plan

Caffeine 6mg/kg

Drug

Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing

Primary outcomes

  1. Quality of life

    Time frame: during test 1 and 3

  2. Maximum walking distance

    Time frame: during treadmill test

Secondary outcomes

  1. Painfree Walking Distance

    Time frame: treadmill test

  2. Max muscle strength (MVC) of kneeextension

    Time frame: At end of each test

  3. Endurance of 50%MVC kneeextension

    Time frame: At end of each test

  4. Postural stability

    Time frame: in all tests

  5. Reaction speed

    Time frame: in all tests

  6. Cognitive function

    Time frame: in all tests

  7. Walking Impairment Questionnaire

    Time frame: in first and third test

  8. vascular endothelian growth factors VGF. FGF

    Time frame: before and after 1. and 2. test

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Central Jutland Regional Hospital
  • Herning Hospital

Registry information

Official study title

Effects of Caffeine in Patients With Intermittent Claudication.

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Oct 13, 2006
Registry last updated
Jun 9, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.